virological outcome and metabolic in virologically suppressed patients living with HIV after switching from ritonavir-boosted protease inhibitor to dolutegravir-base regimen in HIV , ritonavir-boosted protease inhibitor , dolutegravir , metabolic , virological
Conditions
Interventions
dolutegravir 50mg 1 tablet per oral once daily
Experimental Drug
dolutegravir
Sponsors
Khon Kaen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: -people living with HIV -age above 18 years -on protease inhibitor at least 3 month before study -HIV virological <50 copies/ml
Exclusion criteria
Exclusion criteria: - pregnancy or breast feeding - drug resistance to dolutegravir -unstable condition or active OI -on drug that interaction with dolutegravir -autoimmune, Grave disease, Guillain-Barre syndrome -Child-Pugh C -depression or suicidal idea
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cholesterol 6 month after intervention blood cholesterol | — |
Secondary
| Measure | Time frame |
|---|---|
| LDL 6 month after intervention blood for LDL,triglyceride 6 month after intervention blood for triglyceride ,body weight 6 month after intervention direct Measurement,HDL 6 month after intervention blood for HDL ,HIV viral load 6 month after intervention blood for HIV viral load ,CD4 6 month after intervention blood for CD4 | — |
Countries
Thailand
Contacts
Public Contacttharatorn nuntawit
Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen
Outcome results
None listed